Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation (IMRX) is a clinical-stage biopharmaceutical company leveraging computational biology to advance oncology and neurology therapeutics. This news hub provides investors and researchers with essential updates on the company's scientific progress, strategic partnerships, and regulatory developments.
Access real-time announcements about clinical trial milestones, research collaborations, and platform innovations. Our curated collection includes earnings reports, regulatory filings, and analyses of the company's proprietary Disease Cancelling Technology platform. Stay informed about developments in key therapeutic areas including cancer neuroscience and precision oncology targets.
Key updates cover partnership expansions with pharmaceutical leaders, preclinical data publications, and progress toward IND submissions. The resource serves both technical experts seeking molecular mechanism insights and investors monitoring pipeline progression. Content is rigorously verified to ensure accuracy across scientific and financial disclosures.
Bookmark this page for streamlined access to Immuneering's latest advancements in translational bioinformatics and therapeutic candidate development. Regularly updated to reflect new developments in computational drug discovery and clinical-stage research programs.
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place from September 4-6, 2024, at the Marriott Marquis in New York City.
Key executives, including CEO Ben Zeskind and CSO Brett Hall, will present in a fireside chat format on September 6 from 10:00 – 10:35 am ET. They will discuss Immuneering's pipeline, platform, and business strategy, focusing on their development of universal-RAS/RAF medicines for broad populations of cancer patients.
The presentation will be webcast live and archived on Immuneering's website in the Investor Relations section. This event provides an opportunity for investors to gain insights into the company's progress and future plans in the oncology field.
Immuneering (Nasdaq: IMRX) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Enrollment progressing well in IMM-1-104 Phase 2a trial, with initial data from multiple arms expected in 2H 2024.
2. FDA Fast Track Designation granted for IMM-1-104 in first-line pancreatic cancer.
3. Preclinical data presented at AACR showing IMM-1-104 combined with chemotherapies yields deeper tumor growth inhibition in pancreatic cancer models.
4. Initial PK, PD, and safety data from IMM-6-415 Phase 1/2a trial expected in 2H 2024.
Financial highlights: Cash position of $59.7 million as of June 30, 2024. Q2 2024 R&D expenses were $10.7 million, G&A expenses were $4.3 million, and net loss was $14.1 million ($0.47 per share). Cash runway expected to fund operations into 2H 2025.
Immuneering (Nasdaq: IMRX) has received FDA Fast Track designation for IMM-1-104 as a first-line treatment for pancreatic ductal adenocarcinoma (PDAC). This follows the February 2024 Fast Track designation for second-line PDAC treatment. IMM-1-104 is designed to provide universal-RAS activity through Deep Cyclic Inhibition of the MAPK pathway with once-daily oral dosing.
The ongoing Phase 2a trial includes multiple arms evaluating IMM-1-104 in combination with chemotherapy for first-line PDAC patients, as monotherapy for first and second-line PDAC, and for RAS-mutant melanoma and lung cancer. Immuneering expects to share initial data from multiple arms in the second half of 2024.
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, announced its participation in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City from June 5-6, 2024. The company's management team, including CEO Ben Zeskind and Chief Accounting Officer Mallory Morales, will discuss their pipeline, platform, and business strategy. The presentation is scheduled for June 5 from 4:30 – 4:55 pm ET in Track 2 and will be webcast live. The webcast will be archived in the Investor Relations section of Immuneering's website.
Immuneering (Nasdaq: IMRX) reported positive topline results from Phase 1 portion of the Phase 1/2a clinical trial of IMM-1-104 in RAS-Mutant Solid Tumors. First patient dosed in Phase 2a portion with initial data expected in 2024. Preclinical data combining IMM-1-104 with chemotherapies indicated improved tumor growth inhibition. Phase 1/2a trial of IMM-6-415 initiated for advanced solid tumors with RAF or RAS mutations. Fast Track designation received for IMM-1-104 in Pancreatic Cancer. Financially, cash position at $71.3 million as of March 31, 2024, with net loss of $14.3 million for Q1 2024.
Immuneering , a clinical-stage oncology company, is focused on developing universal-RAS/RAF medicines for cancer patients. The company is recognizing Melanoma Awareness Month by highlighting RAS mutant melanoma as the focus of its Phase 2a clinical study for IMM-1-104. Additionally, they are evaluating melanoma in their Phase 1/2a study of IMM-6-415. Immuneering expects to release initial data from multiple Phase 2a arms in 2024.
FAQ
What is the current stock price of Immuneering (IMRX)?
What is the market cap of Immuneering (IMRX)?
